A Pilot Phase I Randomized Study to evaluate Innate Immune Activation predictors of sustained viral control in HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption after the administration of Pegylated Interferon Alpha 2b in Combination with Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074
-
- STATUS
- Recruiting
-
- participants needed
- 12
Summary
Our pilot study will evaluate whether the activation of antiviral innate mechanisms by administration of Pegylated Interferon alpha 2b (peg-IFN-2b) when combined with two broadly neutralizing antibodies (3BNC117 and 10-1074) in HIV positive participants with well controlled viral replication can result in viral control in the absence of ART or immune based therapy during a monitored analytical treatment interruption.
Details
| Condition | Medical Research |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | TBD |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.